Key Highlights

  • A TradingView screener recorded ASX:EIQ near AUD 1.285 and down about 3.8 per cent, an unverified point-in-time reading Kalkine could not confirm against official ASX data; a second snapshot indicated 4 per cent.
  • The 27 July Appendix 4C showed nil receipts from customers for the June quarter and the twelve months to 30 June 2026, operating outflows of AUD 10.565 million and cash of AUD 8.712 million before the roughly AUD 110 million July placement.
  • EchoSolv AS holds a single FDA 510(k) clearance (K241245, October 2024); EchoSolv HF remains under review, and the Pro Medicus investment and distribution arrangement is still subject to definitive documentation.
  • A July institutional placement raised approximately AUD 110 million after the June-quarter reporting date.

The AI echocardiography group banked roughly AUD 110 million from institutions in July and signed a binding heads of agreement with Pro Medicus. Its June-quarter Appendix 4C also recorded no customer receipts for the full financial year, and the shares eased.

Why the stock is in focus

EchoIQ Limited has become one of the more polarising names on the ASX healthcare board. The Sydney company sells artificial-intelligence decision support for echocardiography, and its shares have re-rated violently: ASX-sourced data puts the 52-week range at roughly AUD 0.165 to AUD 1.875, a striking spread for a business now valued near AUD 1 billion.

That re-rating met fresh numbers on 27 July 2026, when EchoIQ lodged its June-quarter Appendix 4C. Software usage is climbing and a large raising was banked just after balance date, yet the cash-flow statement records no customer receipts at all, for either the quarter or the full year to 30 June 2026.

The share-price movement

A TradingView screener of Australian decliners recorded ASX:EIQ at around AUD 1.285, down roughly 3.8 per cent in a single session. That figure is a point-in-time screener reading rather than a verified closing price, and Kalkine has not been able to independently confirm it against official ASX market data.

Two client snapshots of the same session disagreed, one showing about 3.8 per cent, the other about 4 per cent. A separate ASX-sourced feed accessed that day showed a traded range near AUD 1.25 to AUD 1.33 and a market capitalisation around AUD 968 million on about 739.3 million shares.

Latest announcement or development

The June-quarter report was the only price-sensitive disclosure before the fall, making it the most plausible proximate trigger, though EchoIQ has not commented and the link remains inferential.

EchoIQ confirmed a binding heads of agreement with imaging software group Pro Medicus Limited, an institutional placement of approximately AUD 110 million completed after quarter-end, a binding term sheet with Advara HeartCare over a large deidentified echocardiography dataset, and a new chief financial officer in Matthew Dodds. It also disclosed that the EchoSolv HF submission to the United States Food and Drug Administration remains under review, noting device review timeframes have lengthened industry-wide amid reported resource constraints.

Recent financial and operational performance

The Appendix 4C shows net cash used in operating activities of AUD 2.733 million for the quarter and AUD 10.565 million for the twelve months to 30 June 2026, with staff costs of AUD 5.953 million dominating the annual outflow. Cash fell from AUD 11.140 million to AUD 8.712 million over the quarter. The half-year accounts to 31 December 2025 sit behind an ASX access interstitial, so no statutory revenue figure is asserted here.

EchoIQ processed more than 10,200 echocardiograms in the quarter, up about 20 per cent sequentially and more than 400 per cent year-on-year, taking cumulative calendar-2026 processing past 20,000 studies. The pipeline was put at more than 70 hospitals and health systems, with three enterprise proposals covering over 300 US hospitals, which the company stressed are prospects, not contracts. EchoSolv AS was deployed into the Mount Sinai Health System in April.

Business model and principal assets

EchoSolv AS is the only product with United States clearance. The FDA 510(k) database records one entry for the applicant, K241245, cleared as substantially equivalent on 4 October 2024 under radiology product code POK. The software reads measurements already captured during a routine echocardiogram rather than analysing images, returning a structural-heart risk flag in seconds.

The underlying asset is data. The algorithms draw on one of the largest echocardiographic measurement collections available, built on the National Echo Database Australia, and the Advara term sheet adds exclusive access to between 500,000 and one million deidentified studies. Two programs lower the adoption barrier: EchoSolv VIEW runs the algorithm across a prospect's historical studies before purchase, and EchoSolv SHADOW runs alongside live workflow without influencing patient care. Both help explain why volumes climb while receipts do not.

Growth opportunities

Pro Medicus is the standout. It would invest an initial AUD 10 million through secured convertible notes, with an option for a further AUD 10 million subject to FDA clearance of EchoSolv HF, and would gain rights to market the suite through its US health-system network. EchoIQ qualifies that definitive documentation is still being negotiated. This is a proposed transaction, not a completed one.

EchoSolv HF is the second leg; its 510(k) sits with the FDA and no clearance appears in the agency's database. Reimbursement is the third: EchoIQ points to a CMS proposal assigning software-as-a-medical-service technologies to New Technology Ambulatory Payment Classifications on an interim basis, and intends to apply once heart-failure clearance arrives. Kalkine could not verify any CPT code or add-on payment.

Balance sheet, funding and cash flow

At 30 June 2026 EchoIQ held AUD 8.712 million in cash with no undrawn facilities disclosed, and the Appendix 4C's own arithmetic put estimated funding at 3.2 quarters. That excludes the roughly AUD 110 million placement completed after balance date, which transforms the position.

Dilution is the trade-off. The six-month announcement record is dotted with quotation applications and cleansing notices, consistent with steady issuance from options and performance rights, and the proposed Pro Medicus notes would add secured debt and a conversion overhang. Proceeds are earmarked for US commercial expansion and roughly doubling research and development capacity.

Principal risks

Regulatory timing comes first: EchoIQ has one cleared product and a second awaiting a decision it does not control. Commercial conversion comes second. Volumes and pipeline counts are leading indicators, not revenue, and until receipts appear in the cash-flow statement investors are underwriting a conversion assumption rather than observing one.

Competition is intensifying. The same FDA product code now includes GE Medical Systems' Automated Aortic Stenosis Software, cleared in March 2026, alongside Ultromics' EchoGo Pro. An incumbent ultrasound vendor bundling aortic stenosis detection into its own machines is a different proposition. Add key-person exposure, integration dependence and possible further dilution.

Valuation and investor expectations

Conventional multiples are of limited use. With trailing earnings per share of about negative AUD 0.025 on ASX-sourced data, the price-to-earnings ratio is not meaningful, and with no customer receipts a price-to-sales multiple cannot be struck on a cash basis. EV/EBITDA is unusable while EBITDA is negative, and there is no dividend.

Against a market capitalisation of roughly AUD 968 million to AUD 972 million depending on the source, cash of AUD 8.712 million plus about AUD 110 million raised in July is a modest slice of the equity value. Almost all of the market's assessment rests on commercialisation the platform has yet to demonstrate. Prices and multiples change continuously.

Outlook

An investor webinar called for 30 July gives management its first structured chance to explain the quarterly, and the FDA decision on EchoSolv HF is the largest binary event ahead. Definitive Pro Medicus documentation is the next checkpoint.

For shareholders, the number that matters in the September-quarter Appendix 4C is simple: whether the receipts-from-customers line moves off zero. Volume growth, pipeline breadth and dataset scale support the case that EchoIQ has built something clinically useful. None of them yet shows hospitals will pay for it at scale.